InflaRx Presentation: Anti-C5a antibody Vilobelimab (IFX-1) treatment in patients with ulcerative pyoderma gangrenosum: Phase 2, open-label dose escalation trial
Speaker:
Afsaneh Alavi, M.D., Associate Professor of Dermatology at the Mayo Clinic
Date:
Mar 26, 2022
Time:
11:20 AM - 11:30 AM
Presentation
<< back to list